| Scale | Baseline(BL) | Aftertherapy(END) | p Value(BL vs END) | Follow-up(FU) | p Value(BL vs FU) |
| QoL-RLS12 | 28.6 (12.8) | 23.4 (13.1) | <0.001 | 21.2 (9.7) | 0.001 |
| SCL-90-R14 | 51.3 (37.0) | 45.9 (32.9) | 0.031 | 43.7 (34.8) | 0.001 |
| WBS-515 | 12.7 (4.6) | 13.6 (4.3) | 0.207 | 14.8 (4.2) | 0.034 |
| SF-36: mental component summary13 | 46.0 (11.7) | 47.4 (10.9) | 0.445 | 49.8 (7.9) | 0.026 |
| SF-36: physical component summary13 | 45.4 (9.3) | 45.7 (10.4) | 0.978 | 44.8 (9.6) | 0.854 |
| IRLS total score16 | 25.9 (6.9) | 19.1 (6.3) | <0.001 | 18.9 (7.0) | <0.001 |
| IRLS subscale: impact of RLS on daily life16 | 6.0 (2.3) | 4.2 (1.9) | <0.001 | 4.0 (1.7) | <0.001 |
| IRLS subscale: severity of RLS symptoms16 | 15.1 (3.4) | 11.1 (2.7) | <0.001 | 11.3 (4.4) | <0.001 |
| RLS-6: severity at bedtime17 | 5.2 (3.3) | 3.1 (2.7) | 0.008 | 3.0 (2.6) | 0.004 |
| RLS-6: severity during the night17 | 4.4 (3.5) | 3.4 (2.7) | 0.096 | 3.7 (2.9) | 0.339 |
| RLS-6: severity during the day when at rest17 | 2.7 (2.5) | 1.7 (1.6) | 0.010 | 1.8 (2.0) | 0.077 |
| RLS-6: satisfaction with sleep17 | 6.4 (2.4) | 4.5 (2.6) | 0.009 | 5.0 (2.2) | 0.035 |
Values are given as mean (SD). Results of the mid-treatment evaluation are reported in the text.
BL, baseline evaluation; END, evaluation at the end; FU, evaluation 3 months after the end of therapy; QoL-RLS, Quality of life in RLS (0 = excellent, 54 = very bad. Note: item 8, asking for side effects of medication, was omitted); SCL-90-R, Symptom Check List-90 Revised Version (population-based reference value: 50 (10)); WBS-5, WHO-5 Well-Being Scale (0 = very bad, 25 = excellent; scores ⩽ 13 indicative of depression); IRLS, International RLS Severity Scale (0 = no symptoms, 40 = very severe symptoms); IRLS impact subscale, sum score of the IRLS items 5, 9 and 10 (0 = no impairment, 12 = very much impaired); IRLS severity subscale, sum score of the IRLS items 1, 2, 4, 6, 7 and 8 (0 = no symptoms, 24 = very severe symptoms); RLS-6 scales, for each item: 0 = no symptoms, 10 = very severe symptoms.